secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0001689548-26-000031
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports positive EMBRAVE Part A data for elsunersen; FDA grants priority review for relutrigine
--------------------------------------------------------------------------------

- Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in 9-patient Phase 1/2 trial.
- 57% of elsunersen patients had ≥28-day seizure freedom; improvements in sleep, motor function, attention.
- Relutrigine NDA accepted for priority review by FDA with PDUFA target date of September 27, 2026.
- Elsunersen well tolerated; no drug-related SAEs, no discontinuations, no neuroinflammation at doses up to 8 mg.
- All 9 patients continued into open-label extension; efficacy sustained for up to one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/0001689548-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/prax-20260406.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer